Скачать или смотреть VolitionRx Limited (VNRX) Q1 2025 Earnings – Full Coverage

*VolitionRx Limited (VNRX) Q1 2025 Earnings – Full Coverage*

*Key Highlights:*
*Financials* – Q1 2025 revenue $0.25M (+44% YoY), operating expenses -35%, net cash used $4.3M (-48%), cash $2.6M, raised $10.15M (offering, loans, grants).
*Operations* – First Nu.Q Nets human revenue in EU, 9 hospital networks testing, lung cancer study enrolled 100+ patients, Nu.Q Discover in Phase IIb trial.
*Strategy* – CEO Cameron Reynolds emphasized licensing talks with 10+ firms ($600B+ market cap), Nu.Q Nets CE Mark sales, and Nu.Q Vet automation.
*Outlook* – Targets cash flow neutrality in 2025, expects licensing deals, Nu.Q Nets clinical use in EU 2026, lung cancer study results by October.

*Timestamps:*
[00:00] – Opening Remarks and Introduction
[00:51] – Safe Harbor Statement (Louise Batchelor)
[02:34] – Financial Results (Terig Hughes)
[04:57] – Business Update: Licensing and Cancer (Cameron Reynolds)
[09:37] – Nu.Q Nets Commercialization
[12:30] – Nu.Q Vet and Automation
[15:35] – Nu.Q Discover and Clinical Trials
[21:06] – Q&A Session Begins
[21:06] – Operating Expense Sustainability (Ilya Zubkov)
[22:53] – Feline Cancer Test Progress
[24:17] – Nu.Q Vet Partner Engagement (Steven Ralston)
[26:23] – Marketing Expense Outlook
[28:50] – Nu.Q Discover Revenue Timing

*Keywords:* VolitionRx, Q1 2025 earnings, VNRX stock, Nu.Q, cancer diagnostics, sepsis, veterinary, licensing, pharmacoepigenetics

*Buy, Hold, or Sell?*
VolitionRx Limited (VNRX) is a **BUY**. Licensing momentum, Nu.Q Nets revenue, and cost cuts outweigh lumpy revenue and cash burn risks.

*Max Position* – Allocate *3-5%* in a diversified portfolio.

*Comment below with your thoughts! Subscribe for more updates!*
*Full Details:* [VolitionRx Investor Relations](https://ir.volition.com/)

*Disclaimer:* This video includes segments from the earnings call by VolitionRx Limited, used solely for educational and informational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by VolitionRx Limited is implied. All rights to the original content remain with the company. For the official call, visit [https://ir.volition.com/](https://ir.volition.com/). For inquiries or requests for removal, please contact us at [email protected].